Atopic dermatitis or atopic eczema is a chronic, relapsing, familial, symmetric and pruritic inflammatory skin disease that commonly presents during early infancy and childhood, but can persist or start in adulthood.
It is commonly associated with elevated serum immunoglobulin E levels and a personal or family history of allergies, allergic rhinitis and asthma.
It is one of the most common skin diseases afflicting both children and adults.
Patients with moderate-to-severe atopic dermatitis may benefit from a 52-week treatment course of dupilumab in addition to standard-of-care treatment, according to the results of the phase III LIBERTY AD CHRONOS* trial.
There is no evidence suggesting that genetically determined decrease in 25-hydroxyvitamin D (25OHD) levels confers an elevated risk of asthma, atopic dermatitis or elevated total serum immunoglobulin E (IgE), according to a recent study.
Low levels of vitamin D due to genetic polymorphism is not associated with increased risks of immune-mediated diseases such as asthma and atopic dermatitis, nor is it linked to increased total serum immunoglobulin E (IgE), in contrast to previous observations from epidemiological studies.
New drug applications approved by US FDA as of 16 - 31 March 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.